Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholecystokinin receptor antagonists.

J D Gardner, R T Jensen

    The American Journal of Physiology
    |May 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Three classes of cholecystokinin receptor antagonists, including cyclic nucleotide derivatives and amino acid derivatives, were identified. These antagonists exhibit specific, reversible actions but differ in their potency against cholecystokinin.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Inflammatory cardiac fibroblast phenotype underlies chronic alcohol-induced cardiac atrophy and dysfunction.

    Life sciences·2020
    Same author

    Estrogen receptor antagonism exacerbates cardiac structural and functional remodeling in female rats.

    American journal of physiology. Heart and circulatory physiology·2016
    Same author

    Alcohol binge drinking: getting to the heart of it.

    American journal of physiology. Heart and circulatory physiology·2016
    Same author

    Cardiac dysfunction in diabetes.

    Life sciences·2012
    Same author

    Continuous distal oesophageal acidification decreases postprandial gastric acidity in healthy human subjects.

    Alimentary pharmacology & therapeutics·2008
    Same author

    The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings.

    Alimentary pharmacology & therapeutics·2006
    Same journal

    Blood coagulation in fish.

    The American journal of physiology·2011
    Same journal

    Renal tubular reabsorption, metabolic utilization and isomeric fractionation of lactic acid in the dog.

    The American journal of physiology·2010
    Same journal

    The inactivation of placental toxin by human serum.

    The American journal of physiology·2010
    Same journal

    Adrenal function following ovariectomy in the rat.

    The American journal of physiology·2010
    Same journal

    Capillary permeability; perfusion of frog and guinea pig hind limbs.

    The American journal of physiology·2010
    Same journal

    Evaluation of protective measures against sunburn.

    The American journal of physiology·2010
    See all related articles

    Area of Science:

    • Pharmacology
    • Medicinal Chemistry

    Background:

    • Cholecystokinin (CCK) plays a significant role in various physiological processes.
    • Developing effective CCK receptor antagonists is crucial for therapeutic applications.

    Purpose of the Study:

    • To review and categorize the known classes of cholecystokinin receptor antagonists.
    • To highlight common features and variations in potency among these antagonists.

    Main Methods:

    • Literature review of cholecystokinin receptor antagonists described since 1979.
    • Categorization based on chemical structure: cyclic nucleotide derivatives, amino acid derivatives, and CCK fragments.

    Main Results:

    • Three distinct classes of CCK receptor antagonists have been identified.

    Related Experiment Videos

  • All antagonists demonstrate specific, reversible, and competitive inhibition of CCK.
  • Significant variability exists in the potency of these antagonists.

    • Conclusions:

    • The diverse chemical structures of CCK receptor antagonists offer various pharmacological profiles.
    • Understanding the potency variations is key for selecting appropriate antagonists for specific therapeutic targets.